• Regulatory
A1M Pharma announces that the company's preclinical studies shows a protective effect of the candidate drug ROSgard™ on bone marrow, in addition to the already established renal protective effect. The company has therefore filed a patent application and will include biomarkers for bone marrow protection in the company's scheduled clinical program for ROSgard™.

While undergoing radiation therapy, the patient's health is put under significant strain as the radioactive substances used to treat the cancer tumours may also cause serious side effects. The kidneys and the bone marrow are the most exposed organs, and the risk of causing injuries to these organs is a highly limiting factor in today's treatment. This limiting factor applies to the total radiation dose that can be administered to the patient as well as the waiting period between each radiation therapy session.

A1M Pharma aims to initiate clinical studies for kidney protection in connection with radiation therapy during the first quarter 2018, and data from the ongoing preclinical studies also show a distinct protective effect on bone marrow.

In view of this important discovery, the company has now filed a patent application with the aim of obtaining patent protection on several important markets. The discovery is considered as a significant step forward in the development of A1M-based pharmaceutical treatments.

– The fact that our candidate drug seems to protect against two of the most central damaging effects occurring in connection with radiation therapy is highly encouraging. The discovery further strengthens our belief that we will be able to contribute to improve the radiation therapy routines while protecting the patient against serious damaging effects, says A1M Pharma's CEO Tomas Eriksson.

– With these data, we are now reviewing the design of the planned clinical program for ROSgard™ in order to also include biomarkers for bone marrow in connection with radiation therapy. For treating physicians, bone marrow protection is a very important factor. Protecting the bone marrow in connection with radiation therapy might make it possible to increase the number of radiation therapy sessions in a shorter amount of time, resulting in a more effective treatment. The addition of these biomarkers will not affect the timeline of our planned clinical studies. The preparations will continue according to the communicated time frame, says A1M Pharma's Head of Development Eddie Thordarson.

About PRRT
The targeted radiation therapy PRRT, mainly used to treat neuroendocrine tumours (NETs) that can spread to the gastrointestinal tract and the lungs, heavily affects the patient's kidneys which may cause serious kidney injuries. Kidney injuries and bone marrow injuries are the limiting factors of the maximum radiation dose that can be used in separate sessions and in total as well as the frequency of the treatments. Potential kidney injuries often do not appear until several months after the treatment. A1M Pharma is therefore developing the candidate drug ROSgard™ to be administered in connection with each radiation therapy session for protection against potential kidney injuries. The first clinical study is scheduled to start in the first quarter of 2018.

For more information, please contact
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

About A1M Pharma
Several preclinical studies indicate that A1M Pharma's candidate drug, ROSgard™, based on the endogenous protein Alpha- 1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and which often limits the possibilities of using radiation therapies as a treatment for cancer. The company's two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) - a targeted radiation therapy for cancer - with the aim of opening the possibility of increasing treatment levels and so fight metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma is listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is information that A1M Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was provided, through the above contact, for publication on the 7 November 2017 at 08.30 CET.
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Member of Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M